Update date
31 Mar 2026
Shareable Research Card
IGC - IGC Pharma, Inc. Increase (Decrease) in Accounts Receivable
This metric view shows IGC - IGC Pharma, Inc. increase (decrease) in accounts receivable history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q1 2026
- Latest reported value
- $24,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Mar 2026
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q1 2026.
- Latest reported value on this page: $24,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Increase (Decrease) in Accounts Receivable
Latest reported increase (decrease) in accounts receivable: $24,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 15 May 2026.
Benchmark Context
How Increase (Decrease) in Accounts Receivable compares with peers
IGC Pharma, Inc. is outside the visible top 120 companies for increase (decrease) in accounts receivable in the current sample.
Compared with
Compared with 120 companies reporting increase (decrease) in accounts receivable in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Increase (Decrease) in Accounts Receivable does not yet have enough prior-period data for a historical comparison on this page.
- Visible rows currently span reported period ends from 31 Mar 2012 to 02 May 2026.
- Nearby companies in this sample: Dell Technologies Inc. and ARROW ELECTRONICS, INC..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
IGC Pharma, Inc.: Increase (Decrease) in Accounts Receivable
Latest period: Q1 2026. Period end: 31 Mar 2026. Units: USD. Frequency: quarterly and annual.
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Metric Snapshot
- Latest value
- $24,000
- Coverage range
- 30 Jun 2010 - 31 Mar 2026
- Fact rows
- 33
What This Metric Tells You
- Shows the reported level of increase (decrease) in accounts receivable over 30 Jun 2010 - 31 Mar 2026.
- Use consecutive periods in the table to assess trend direction when YoY change is unavailable.
- Built from 33 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Increase (Decrease) in Accounts Receivable levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Dell Technologies Inc. (dell) | $7,022,000,000 | Year - 30 Jan 2026 | Open Dell Technologies Inc. Increase (Decrease) in Accounts Receivable |
| 2 | ARROW ELECTRONICS, INC. (arw) | $6,280,326,000 | Quarter - 04 Apr 2026 | Open ARROW ELECTRONICS, INC. Increase (Decrease) in Accounts Receivable |
| 3 | MICROSOFT CORP (msft) | $4,707,000,000 | Quarter - 31 Mar 2026 | Open MICROSOFT CORP Increase (Decrease) in Accounts Receivable |
| 4 | Energy Transfer LP (et) | $4,360,000,000 | Quarter - 31 Mar 2026 | Open Energy Transfer LP Increase (Decrease) in Accounts Receivable |
| 5 | Marathon Petroleum Corp (mpc) | $4,302,000,000 | Quarter - 31 Mar 2026 | Open Marathon Petroleum Corp Increase (Decrease) in Accounts Receivable |
| 6 | UNITEDHEALTH GROUP INC (unh) | $3,544,000,000 | Quarter - 31 Mar 2026 | Open UNITEDHEALTH GROUP INC Increase (Decrease) in Accounts Receivable |
Metric Details
- Metric
- Increase (Decrease) in Accounts Receivable (IncreaseDecreaseInAccountsReceivable)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly and annual
- History range
- 30 Jun 2010 - 31 Mar 2026
- Facts on this page
- 33
- Description
- The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Increase (Decrease) in Accounts Receivable, Quarterly (USD)
Increase (Decrease) in Accounts Receivable, YoY Quarterly Change (%)
Increase (Decrease) in Accounts Receivable, Annual (USD)
Increase (Decrease) in Accounts Receivable, YoY Annual Change (%)
IGC Pharma, Inc. Quarterly Increase (Decrease) in Accounts Receivable (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 | $24,000 | +$26,000 | 01 Jan 2026 | 31 Mar 2026 | 10-Q | 15 May 2026 | 2026 | Q1 | ||
| Q2 2025 | $53,000 | +$64,000 | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 14 Aug 2025 | 2026 | Q1 | ||
| Q1 2025 | $2,000 | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 15 May 2026 | 2026 | Q1 | |||
| Q2 2024 | $11,000 | -$129,000 | -109% | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 14 Aug 2025 | 2026 | Q1 | |
| Q2 2023 | $118,000 | +$95,000 | +413% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 07 Aug 2024 | 2025 | Q1 | |
| Q2 2022 | $23,000 | +$36,000 | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 10 Aug 2023 | 2024 | Q1 | ||
| Q2 2021 | $13,000 | -$170,000 | -108% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 05 Aug 2022 | 2023 | Q1 | |
| Q2 2020 | $157,000 | +$52,000 | +50% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 11 Aug 2021 | 2022 | Q1 | |
| Q2 2019 | $105,000 | -$1,326,000 | -93% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 19 Aug 2020 | 2021 | Q1 | |
| Q2 2018 | $1,431,000 | +$1,344,464 | +1554% | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 09 Aug 2019 | 2020 | Q1 | |
| Q2 2017 | $86,536 | +$448,248 | 01 Apr 2017 | 30 Jun 2017 | 10-Q | 03 Aug 2018 | 2019 | Q1 | ||
| Q2 2016 | $361,712 | -$400,654 | -1029% | 01 Apr 2016 | 30 Jun 2016 | 10-Q | 18 Aug 2017 | 2018 | Q1 | |
| Q2 2015 | $38,942 | -$75,682 | -66% | 01 Apr 2015 | 30 Jun 2015 | 10-Q | 16 Aug 2016 | 2017 | Q1 | |
| Q2 2014 | $114,624 | +$161,385 | 01 Apr 2014 | 30 Jun 2014 | 10-Q | 14 Aug 2015 | 2016 | Q1 | ||
| Q2 2013 | $46,761 | +$7,693 | +14% | 01 Apr 2013 | 30 Jun 2013 | 10-Q | 14 Aug 2014 | 2015 | Q1 | |
| Q2 2012 | $54,454 | +$326,476 | +86% | 01 Apr 2012 | 30 Jun 2012 | 10-Q | 16 Aug 2013 | 2013 | Q1 | |
| Q2 2011 | $380,930 | +$646,147 | +63% | 01 Apr 2011 | 30 Jun 2011 | 10-Q/A | 21 Aug 2012 | 2012 | Q1 | |
| Q2 2010 | $1,027,077 | 01 Apr 2010 | 30 Jun 2010 | 10-Q | 18 Aug 2011 | 2011 | Q1 |
IGC Pharma, Inc. Annual Increase (Decrease) in Accounts Receivable (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | $8,000 | -$17,000 | -68% | 01 Apr 2024 | 31 Mar 2025 | 10-KT | 18 Mar 2026 | 2025 | FY |
| 2023 | $25,000 | +$30,000 | 01 Apr 2023 | 31 Mar 2024 | 10-K | 27 Jun 2025 | 2025 | FY | |
| 2022 | $5,000 | +$45,000 | +90% | 01 Apr 2022 | 31 Mar 2023 | 10-K | 24 Jun 2024 | 2024 | FY |
| 2021 | $50,000 | -$92,000 | -219% | 01 Apr 2021 | 31 Mar 2022 | 10-K | 07 Jul 2023 | 2023 | FY |
| 2020 | $42,000 | -$7,000 | -14% | 01 Apr 2020 | 31 Mar 2021 | 10-K | 23 Jun 2022 | 2022 | FY |
| 2019 | $49,000 | +$523,000 | 01 Apr 2019 | 31 Mar 2020 | 10-K | 14 Jun 2021 | 2021 | FY | |
| 2018 | $474,000 | -$508,000 | -1494% | 01 Apr 2018 | 31 Mar 2019 | 10-K | 13 Jul 2020 | 2020 | FY |
| 2017 | $34,000 | -$110,711 | -77% | 01 Apr 2017 | 31 Mar 2018 | 10-K | 14 Jun 2019 | 2019 | FY |
| 2016 | $144,711 | +$225,172 | 01 Apr 2016 | 31 Mar 2017 | 10-K | 21 Jun 2018 | 2018 | FY | |
| 2015 | $80,461 | +$66,524 | +45% | 01 Apr 2015 | 31 Mar 2016 | 10-K | 14 Jul 2017 | 2017 | FY |
| 2014 | $146,985 | +$227,980 | +61% | 01 Apr 2014 | 31 Mar 2015 | 10-K | 14 Jul 2016 | 2016 | FY |
| 2013 | $374,965 | +$93,341 | +20% | 01 Apr 2013 | 31 Mar 2014 | 10-K | 14 Jul 2015 | 2015 | FY |
| 2012 | $468,306 | +$118,812 | +20% | 01 Apr 2012 | 31 Mar 2013 | 10-K | 15 Jul 2014 | 2014 | FY |
| 2011 | $587,118 | -$593,940 | -8706% | 01 Apr 2011 | 31 Mar 2012 | 10-K | 15 Jul 2014 | 2013 | FY |
| 2010 | $6,822 | 01 Apr 2010 | 31 Mar 2011 | 10-K | 16 Jul 2012 | 2011 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.